Journal article

An evaluation of Admedus' tissue engineering processtreated (ADAPT) bovine pericardium patch (CardioCel) for the repair of cardiac and vascular defects

Geoff Strange, Christian Brizard, Tom R Karl, Leon Neethling



Tissue engineers have been seeking the 'Holy Grail' solution to calcification and cytotoxicity of implanted tissue for decades. Tissues with all of the desired qualities for surgical repair of congenital heart disease (CHD) are lacking. An anti-calcification tissue engineering process (ADAPT TEP) has been developed and applied to bovine pericardium (BP) tissue (CardioCel, AdmedusRegen Pty Ltd, Perth, WA, Australia) to eliminate cytotoxicity, improve resistance to acute and chronic inflammation, reduce calcification and facilitate controlled tissue remodeling. Clinical data in pediatric patients, and additional pre-market authorized prescriber data demonstrate that CardioCel performs extremel..

View full abstract


Funding Acknowledgements

G Strange is a consultant to AdmedusRegen Pty Ltd, and serves as Medical Director, Admedus Ltd. C Brizard has received honorarium for speaking for Admedus Ltd and serves on the scientific Medical advisory Board for Admedus Ltd. TR Karl has received travel grants and honorarium for speaking and serves on the Scientific Medical Advisory Board for Admedus Ltd. L Neethling serves as an advisory consultant to Admedus Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.